Discussion
toxicities, tumor, tumors
PROLIFERATION, TUMOR, TUMORS
In this phase II study, we attempted to improve the antitumor efficacy Given that patients in our study generally had no standard of care, or progressed on multi-line therapy in the advanced-stage of tumor, good tolerance and low toxicities were the major concerning. A clinical trial has shown that hypofractionated radiation therapy (3 fractions of 8 Gy) combined with anti-PD-L1-antibody or anti-CTLA-4 antibody could induce the proliferation of CD8We found the comprehensive therapeutic strategy provided a promising anti-tumor activity for advanced patients with tolerable toxicities, regardless they received prior immuno- or anti-angiogenic therapy or not. Especially, several types of tumors demonstrated promising efficacy and well-tolerate safety that deserve further exploration.